NeOnc Charting New Nasal Route to Treating Brain Cancer

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings’ (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because it is testing a different answer to one of the field’s oldest problems.

The disease is aggressive. Patients may have already undergone surgery, radiation and temozolomide. Once the tumor returns, treatment options narrow, and the central problem is not simply finding another molecule that can kill cancer cells. It is getting an effective amount of that molecule to the right place without creating unacceptable toxicity elsewhere.

Recurrent high-grade glioma is where oncology’s promises tend to collide with biology.

NEO100 is an intranasal formulation of purified perillyl alcohol. The Company's basic proposition is straightforward: rather than asking a drug to cross the blood-brain barrier from the bloodstream, deliver it through the nose and attempt to reach the brain through the olfactory pathway. The approach turns drug delivery itself into part of the therapeutic strategy.

On August 12, 2026, NeOnc reported topline results from the Phase 2a portion of NEO100-01, an open-label study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The 24-patient study reported six-month progression-free survival of 48.9%, compared with a 20% benchmark specified in the study design for standard of care. The Company reported a one-sided p-value of 0.0047. Median overall survival was 26.09 months, while overall survival at six months was 86.7%.

Those are attention-getting numbers and one of the next steps could be demonstrating that NEO100 works in a randomized trial and establish that nose-to-brain delivery is superior to conventional systemic treatment.

The Phase 2a study enrolled 24 patients. It was open-label and compared its primary endpoint with a prespecified historical benchmark rather than a concurrent randomized control group. The reported six-month PFS estimate also has a confidence interval of 26.3% to 68.1%, illustrating how much uncertainty remains around an estimate derived from such a small population.

That is precisely what makes the NEO100 story interesting. The experiment is testing two hypotheses at once. The first is therapeutic: can perillyl alcohol meaningfully control recurrent IDH1-mutant high-grade glioma? The second is logistical and biological: can intranasal delivery provide a practical way of getting a drug into the central nervous system?

For decades, the blood-brain barrier has been treated as both a biological defense system and a drug-development obstacle. It protects the brain from potentially harmful substances circulating in the blood, but that protection also prevents many cancer drugs from reaching tumors at therapeutically useful concentrations. Researchers have pursued molecular engineering, nanoparticles, focused ultrasound, convection-enhanced delivery and other strategies to circumvent or temporarily alter the barrier.

An intranasal approach offers a different proposition. Instead of breaking the barrier down, it tries to exploit an anatomical route around it.

The attraction is obvious. A patient in the NEO100 program can self-administer the drug at home. The Company says the recommended regimen is intranasal dosing four times daily in 28-day cycles. The Phase 2a report said no major toxicities were observed and that adverse events were predominantly low-grade.

A treatment that requires hospitalization, infusion infrastructure or repeated invasive procedures carries a burden beyond its pharmacology. A treatment that can be administered by a patient at home potentially changes the practical economics and experience of therapy. For patients living with recurrent brain cancer, avoiding another procedure can be clinically meaningful even before the question of efficacy is settled.

The most intriguing detail in the August readout may be the distribution of outcomes rather than the headline PFS figure. NeOnc reported that five of the 24 patients remained on treatment at the time of the readout. One patient had an ongoing partial response beyond 114 days, while another patient was reported to have remained progression-free for roughly 19 months.

That kind of long tail is precisely what researchers will want to understand.

Is it evidence of a biologically distinct subgroup? Is IDH1 mutation status identifying patients unusually sensitive to the treatment? Is the apparent tail reproducible? Or does a small sample simply make unusual individual outcomes disproportionately visible?

NeOnc pointed to a biological rationale involving IDH1-mutant tumors, saying earlier Phase 1 experience had shown long-term survivors carrying an IDH1 mutation. That is an interesting hypothesis, but a hypothesis is not the same as a validated predictive biomarker.

NeOnc has said it intends to request a Type B meeting with the FDA to discuss a potential registrational path for NEO100 in recurrent IDH1-mutant high-grade glioma. The question for regulators will not simply be whether the Phase 2a result cleared its prespecified statistical benchmark. It will be whether the design, population, endpoint and magnitude of the observed effect provide an adequate foundation for the next development step.

That is where the distinction between a promising Phase 2a study and a medicine becomes unavoidable.

A successful oncology drug has to survive multiple forms of scrutiny: statistical, clinical, manufacturing, regulatory and practical. The more unusual the delivery mechanism, the more important it becomes to demonstrate not merely that patients received the drug, but that the delivery strategy produces clinically meaningful benefit.

Brain-cancer drug development often becomes a contest between elegant biology and brutal logistics. A molecule can look compelling in a laboratory and fail because insufficient drug reaches the tumor. A delivery technology can look ingenious and fail because the therapeutic payload is not sufficiently active. NEO100 is attempting to solve both problems with one strategy.

That is a high bar and the encouraging part is that the Phase 2a study appears to have generated a signal worth investigating.

The more interesting conclusion is that NEO100 has made the blood-brain barrier itself part of the clinical experiment.

If larger and better-controlled studies reproduce the signal, the significance could extend beyond perillyl alcohol or NeOnc. It would strengthen the case for intranasal delivery as a genuine CNS-development strategy.

The nose spray has not yet changed brain-cancer care, but it has, however, produced enough evidence to make the question worth asking seriously.

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.